NAS8
NOTICE OF ACCEPTANCE OF SEC. 8 - E-MAILED
10/04/2026
Voltar para busca
Dado oficial do USPTO
CIPLA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
24
Atualização mais recente
11/04/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
26/10/2018
Data de registro
29/10/2019
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
10/04/2026
Última transação
11/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
701
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
Mumbai, Maharashtra, IN
Examinador
NITKIN, DINISHA F
Localização atual
Historical data usage
Titulares e representantes
Titulares
CIPLA LIMITED
Representantes
Stacey R. Halpern Knobbe, Martens, Olson & Bear, LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and medicinal preparations for the treatmentalleviation and prevention of gastro-intestinal disordersdisorders of the central nervous systemencephalitisepilepsyAlzheimer'scerebral palsyParkinson's diseaseseizures Huntington's diseasemultiple sclerosis; Pharmaceutical and medicinal preparations for the treatmentalleviation and prevention of disorders of the respiratory systemheart conditions and other disorders of the cardiovascular systemCoronary artery diseaseHeart attackabnormal heart rhythmsarrhythmiasheart failureheart valve diseasecongenital heart diseasecardiomyopathypericardial disease; Pharmaceutical and medicinal preparations for the treatmentalleviation and prevention of migraines and other forms of headachesinus headachestension headachescluster headaches and rebound headaches; pharmaceutical and medicinal preparationsanalgesics; pharmaceutical and medicinal preparationsantiviral and anti-retroviral pharmaceutical preparations for the treatment of viral brain diseases; pharmaceutical and medicinal preparationsanti-infectives; pharmaceutical and medicinal preparationsanti-inflammatories; pharmaceutical and medicinal preparationsantibiotics; pharmaceutical and medicinal preparationsantidepressants; pharmaceutical and medicinal preparationsanti-cancer preparations; pharmaceutical and medicinal preparationsmedicated soaps and lotions for the skin and hairmedicated acne lotionmedicated body moisturizing lotionmedicated lotion for eczema and seborrheic dermatitismedicated hair shampoo and hair scalp lotionmedicated anti-dandruff lotion; pharmaceutical and medicinal preparationsdecongestants and antihistamines; pharmaceutical and medicinal preparationsscabicides; pharmaceutical and medicinal preparationsanti-malarials; pharmaceutical and medicinal preparationscough suppressants; pharmaceutical and medicinal preparationscough and cold preparations; pharmaceutical and medicinal preparationsexpectorants; pharmaceutical and medicinal preparationsanti-leukemic agents; pharmaceutical and medicinal preparationstissue sealants; pharmaceutical and medicinal preparationsvasopressors; pharmaceutical and medicinal preparationsnondepolarizing skeletal neuromuscular blocking agents; pharmaceutical and medicinal preparationspreparations for the treatment of gout; pharmaceutical and medicinal preparationspreparations for cessation of smoking; Pharmaceutical and medicinal preparations for the treatmentalleviation and prevention of genitourinary diseases and disordersurological diseasesurological disordersurinary incontinenceinfertilitysexually transmitted diseasesinflammatory pelvic diseases; Pharmaceutical and medicinal preparations for the treatmentalleviation and prevention of pain from burnshemolytic diseases and disordersneuropathic pain; Pharmaceutical and medicinal preparations for the treatmentalleviation and prevention of fibromyalgiapost-herpetic neuralgiachronic painobesityinflammation and inflammatory diseasesinflammatory bowel diseasesinflammatory connective tissue diseasesimmunological diseases and disordersautoimmune diseasesimmunologic deficiency syndromesAcquired Immune Deficiency Syndrome (AIDS)viral diseases and disordersherpeshepatitissubstance abuse disordersalcoholism and drug addictioncarpel tunnel syndromevaricose veinsdental and oral diseasesosteoporosisarthritisyeast infectionsprostate disorderspulmonary disorderssleep disordersinsomnia andrestless leg syndromepremature ejaculationmacular degenerationthrombosis and thromboembolism; pharmaceutical and medicinal preparationsvaccines for human use; pharmaceutical and medicinal preparationsadjuvants for use with human vaccines; pharmaceutical and medicinal preparations in the nature of veterinary preparationsflea and tick preparationsvaccinesanti inflammatoriesmastitis preparationsoncological preparations
Publicações
Histórico de despachos e eventos da marca no USPTO.
24 publicações encontradas
8.OK
REGISTERED - SEC. 8 (6-YR) ACCEPTED
10/04/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
20/03/2026
ES8R
TEAS SECTION 8 RECEIVED
29/10/2025
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
29/10/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
29/10/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
13/08/2019
PUBO
PUBLISHED FOR OPPOSITION
13/08/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
24/07/2019
ALIE
ASSIGNED TO LIE
08/07/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
27/06/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
27/06/2019
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
27/06/2019
GNEA
EXAMINERS AMENDMENT E-MAILED
27/06/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
27/06/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
07/06/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/06/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/06/2019
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
04/02/2019
GNRT
NON-FINAL ACTION E-MAILED
04/02/2019
CNRT
NON-FINAL ACTION WRITTEN
04/02/2019
DOCK
ASSIGNED TO EXAMINER
04/02/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/11/2018
NWAP
NEW APPLICATION ENTERED
30/10/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CIPLA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.